Ospemifene
Ospemifene (Osphena) is an oral SERM FDA-approved for moderate to severe dyspareunia and vaginal dryness in menopause — the only oral non-estrogen option.
How it works
Ospemifene is a selective estrogen receptor modulator (SERM) — it acts as an estrogen agonist in vaginal tissue (improving dryness and reducing dyspareunia) but as an estrogen antagonist in breast tissue. This tissue-selective profile is what allows ospemifene to treat genitourinary syndrome of menopause (GSM) without the systemic estrogen exposure of HRT. It is the only oral medication FDA-approved for dyspareunia and vaginal dryness related to menopause, and is an alternative to vaginal products for women who prefer oral administration. Clinical trials showed statistically significant improvement in vaginal cell maturation, vaginal pH, and dyspareunia severity.
Ospemifene carries a risk of venous thromboembolism (similar to estrogen) and should not be used in women with a history of blood clots or stroke. Like estrogen, it has an endometrial effect — a progestogen may be required if there is concern about endometrial stimulation; this should be discussed with a physician. Hot flashes are a recognized side effect and occur in approximately 7% of users.
How to track Ospemifene
- Dyspareunia (painful intercourse) — the primary FDA-labeled indication; rate severity before starting and track weekly.
- Vaginal dryness and discomfort — the broader symptom target; track separately from dyspareunia.
- Hot flashes — ospemifene can cause or worsen hot flashes in some people; log frequency and severity.
- Leg pain or swelling — signs of potential thromboembolism, which is a risk with SERMs; log any episodes and seek prompt medical attention.
- Bleeding or spotting — any vaginal bleeding warrants prompt physician review on any SERM.
- Rate dyspareunia before starting and weekly thereafter — ospemifene's effect on vaginal tissue is gradual, and a consistent scale allows you to see the trajectory.
- Log hot flashes before and after starting — ospemifene can cause or worsen them; your pre-treatment baseline shows whether the medication is contributing.
- Log any leg pain, swelling, or redness immediately and contact your physician — these symptoms can indicate thrombosis, which is a known SERM risk.
- Track vaginal dryness separately from dyspareunia — they often improve on related but distinct timelines.
- Log any spotting or bleeding with date and description — this is clinically important on any SERM.
Questions to ask your physician
- My dyspareunia severity rating before starting was [X]. At [N] weeks on ospemifene, my current rating is [Y]. Is that response within the expected range?
- I've been logging hot flash frequency before and after starting — here is the comparison. Is the change attributable to ospemifene?
- I've logged [X] episodes of spotting since starting — here is the pattern. Does that require further evaluation?
- My history includes [risk factor for thromboembolism]. Given ospemifene's thromboembolic risk, should we reassess whether this is the most appropriate treatment for my GSM symptoms?